Zobrazeno 1 - 10
of 131
pro vyhledávání: '"неалкогольный стеатогепатит"'
Autor:
K. V. Menshikov, A. V. Sultanbaev, Sh. I. Musin, I. R. Rakhmatullina, I. A. Menshikova, R. R. Abdeev, N. I. Sultanbaeva, E. V. Popova, G. A. Serebrennikov
Publikováno v:
Креативная хирургия и онкология, Vol 12, Iss 2, Pp 139-150 (2022)
Liver cancer remains a global challenge of healthcare, with the incidence growing worldwide. According to various authors, over 1 million patients will be diagnosed with liver cancer each year by 2025. The molecular pathogenesis of HCC varies with re
Externí odkaz:
https://doaj.org/article/c14b45b6db8241569154b21ca73ae506
Publikováno v:
University Therapeutic Journal, Vol 4 (2022)
Externí odkaz:
https://doaj.org/article/bfdff612f42a44e4a1874a1cec2e3451
Autor:
M. V. Mayevskaya, M. A. Morozova
Publikováno v:
Российский журнал гастроэнтерологии, гепатологии, колопроктологии, Vol 26, Iss 4, Pp 55-61 (2018)
Aim of review. To consider different treatment options for dyslipidemia in non-alcoholic fatty liver disease (NAFLD). Summary. NAFLD occurs in 20-30% of adult population. In the Russian Federation its rate is estimated as high as 37,1%. In the most o
Externí odkaz:
https://doaj.org/article/233cdd5650d243ed9c8a52c8f85a88db
Publikováno v:
Journal of Education, Health and Sport, Vol 6, Iss 4, Pp 281-286 (2016)
Levitsky A. P., Tkachuk V. V., Velichko V. I., Vasyuk V. L. Профилактика ожирения и неалкогольного стеатогепатита у крыс антидисбиотическим средством = Prevention and tr
Externí odkaz:
https://doaj.org/article/3a82ee2b6cf34412a97d40104f7392bd
Autor:
I. N. Grigorieva, Y. M. Pozdnyakov
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 5, Iss 6, Pp 51-54 (2016)
Results of combined therapy of gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and hypercholesterolemia (HCE) with statins and ursodeoxycholic acid (UDCA) are analyzed. In GSD statin therapy wa
Externí odkaz:
https://doaj.org/article/0defd67051ff4d2683d99a106c112162
Autor:
O. M. Drapkina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 9, Iss 2, Pp 143-148 (2015)
Questions of statins use in liver diseases are discussed. Data from clinical studies on statins safety in cardiac patients with liver diseases are presented. Features of statins use in nonalcoholic fatty liver disease, viral hepatitis C are considere
Externí odkaz:
https://doaj.org/article/930da7f7115b4f0292d8eeceb092c6c1
Publikováno v:
Лекарства Украины; № 8(264) (2022); 18-21
Medicine of Ukraine; No. 8(264) (2022); 18-21
Ліки України; № 8(264) (2022); 18-21
Medicine of Ukraine; No. 8(264) (2022); 18-21
Ліки України; № 8(264) (2022); 18-21
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the developed world. NAFLD is encompasses a spectrum of liver manifestations ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), fibrosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::ade0a49e1c1e06bb4258c8a1f3a2459f
http://lu-journal.com.ua/article/view/271835
http://lu-journal.com.ua/article/view/271835
Publikováno v:
Медицинский совет, Vol 0, Iss 3-2, Pp 46-51 (2013)
More than 30 years ago, Jurgen Ludwig et al. from Mayo Clinic (USA, Minnesota) for the first time at biopsy described typical signs of parenchyma lesions in alcoholic liver disease in patients who did not consume hepatotoxic doses of alcohol but were
Externí odkaz:
https://doaj.org/article/2c6a656aa7774c20861f503febaa61ef
Publikováno v:
Буковинський медичний вісник; Том 24, № 3 (95) (2020); 143-150
Буковинский медицинский вестник; Том 24, № 3 (95) (2020); 143-150
Bukovinian Medical Herald; Том 24, № 3 (95) (2020); 143-150
Буковинский медицинский вестник; Том 24, № 3 (95) (2020); 143-150
Bukovinian Medical Herald; Том 24, № 3 (95) (2020); 143-150
Мета роботи – з’ясувати ймовірний вплив метадоксину та смоли гуарової на показники гомеостазу глюкози за коморбідного перебігу неалк
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::098e64c304be7efaf8d461ea72a028a1
https://doi.org/10.24061/2413-0737.xxiv.3.95.2020.85
https://doi.org/10.24061/2413-0737.xxiv.3.95.2020.85
Publikováno v:
Mìžnarodnij Endokrinologìčnij Žurnal, Vol 16, Iss 8, Pp 622-629 (2020)
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine); Vol. 16 No. 8 (2020); 622-629
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16 № 8 (2020); 622-629
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16 № 8 (2020); 622-629
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine); Vol. 16 No. 8 (2020); 622-629
Международный эндокринологический журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16 № 8 (2020); 622-629
Міжнародний ендокринологічний журнал-Mìžnarodnij endokrinologìčnij žurnal; Том 16 № 8 (2020); 622-629
Background. The purpose of the study was to determine the probable effect of a complex of metformin, rosuvastatin, essential phospholipids, and quercetin on the clinical course of non-alcoholic steatohepatitis, diabetic kidney disease, type 2 diabete
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::1a833e9136c19265423ffb92ef1bc4c4
http://iej.zaslavsky.com.ua/article/view/222883
http://iej.zaslavsky.com.ua/article/view/222883